Protagonist Therapeutics Inc (NASDAQ:PTGX) has been given an average recommendation of “Hold” by the seven brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $17.33.

A number of research analysts recently commented on the company. ValuEngine upgraded Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 18th. Zacks Investment Research upgraded Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 11th. Finally, Leerink Swann raised their price target on Protagonist Therapeutics from $13.00 to $21.00 and gave the stock an “outperform” rating in a research report on Monday, August 6th.

PTGX stock traded down $0.22 during trading hours on Friday, hitting $8.77. 39,230 shares of the stock were exchanged, compared to its average volume of 237,147. The stock has a market capitalization of $247.84 million, a price-to-earnings ratio of -4.20 and a beta of 3.68. Protagonist Therapeutics has a 12 month low of $5.50 and a 12 month high of $23.97.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings results on Tuesday, August 7th. The company reported ($0.41) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.07). Protagonist Therapeutics had a negative return on equity of 24.16% and a negative net margin of 56.92%. The company had revenue of $11.67 million during the quarter, compared to the consensus estimate of $8.55 million. Equities research analysts expect that Protagonist Therapeutics will post -1 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. American Century Companies Inc. increased its position in shares of Protagonist Therapeutics by 3.7% in the second quarter. American Century Companies Inc. now owns 148,076 shares of the company’s stock worth $995,000 after purchasing an additional 5,242 shares during the period. Cubist Systematic Strategies LLC increased its position in shares of Protagonist Therapeutics by 255.0% in the first quarter. Cubist Systematic Strategies LLC now owns 11,593 shares of the company’s stock worth $100,000 after purchasing an additional 8,327 shares during the period. Schwab Charles Investment Management Inc. increased its position in shares of Protagonist Therapeutics by 67.4% in the first quarter. Schwab Charles Investment Management Inc. now owns 32,315 shares of the company’s stock worth $278,000 after purchasing an additional 13,015 shares during the period. Bank of New York Mellon Corp increased its position in shares of Protagonist Therapeutics by 26.6% in the second quarter. Bank of New York Mellon Corp now owns 63,269 shares of the company’s stock worth $426,000 after purchasing an additional 13,303 shares during the period. Finally, Prudential Financial Inc. bought a new position in shares of Protagonist Therapeutics in the first quarter worth $116,000. Institutional investors own 57.93% of the company’s stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an oral interleukin-23 receptor antagonist, which is in Phase I clinical trial for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic, which has completed Phase I study for use in the treatment of beta-thalassemia, as well as for treating other diseases, such as hereditary hemochromatosis, polycythemia vera, siderophilic infections, and liver fibrosis.

Recommended Story: Analyzing a company’s cash flow statement

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.